said preliminary data from a study of Xyotax in combination with carboplatin produced a major tumor response in 98% of first-line ovarian cancer patients.
The biopharmaceutical company said the phase II study was for first-line induction and single-agent maintenance therapy of advanced stage III/IV ovarian cancer. The data were reported at the annual meeting of the American Society of Clinical Oncology.
Of the 82 patients studied, 80 patients, or 98%, achieved a major tumor response during the induction phase of the therapy, including 85% with complete response and 12% with partial response.
Some side effects of the treatment included neuropathy, nausea, vomiting, febrile neutropenia and anemia.
Separately, Cell Therapeutics reported initial data from a phase I study of weekly Xyotax given in combination with radiation for patients with esophageal and gastric cancer. Of the 11 patients with loco-regional disease that could be evaluated for tumor response, four patients achieved a complete disappearance of their tumor and five patients achieved a 50% or greater shrinkage of their cancer.